Somewhat Positive News Coverage Somewhat Unlikely to Affect vTv Therapeutics (VTVT) Stock Price

News stories about vTv Therapeutics (NASDAQ:VTVT) have been trending somewhat positive on Friday, according to Accern. The research firm identifies positive and negative news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. vTv Therapeutics earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 47.9607158995934 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:

vTv Therapeutics traded down $0.10, reaching $1.57, during trading on Friday, reports. 993,459 shares of the company’s stock were exchanged, compared to its average volume of 1,114,252. The company has a debt-to-equity ratio of -0.09, a quick ratio of 0.35 and a current ratio of 0.35. vTv Therapeutics has a 1-year low of $0.65 and a 1-year high of $8.40. The firm has a market capitalization of $54.49 million, a PE ratio of -0.94 and a beta of 1.84.

vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings results on Tuesday, May 15th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.04). The business had revenue of $2.06 million during the quarter, compared to the consensus estimate of $3.14 million. equities research analysts predict that vTv Therapeutics will post -1.1 earnings per share for the current fiscal year.

VTVT has been the subject of a number of analyst reports. Seaport Global Securities initiated coverage on vTv Therapeutics in a research report on Thursday, March 29th. They set a “buy” rating and a $14.00 price objective for the company. Roth Capital lowered vTv Therapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $18.00 to $17.00 in a research report on Tuesday, April 10th. Zacks Investment Research upgraded vTv Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, April 13th. Northland Securities lowered vTv Therapeutics from an “outperform” rating to a “market perform” rating and set a $28.00 price objective for the company. in a research report on Tuesday, April 10th. Finally, Piper Jaffray Companies lowered vTv Therapeutics from an “overweight” rating to a “neutral” rating and set a $4.00 price objective for the company. in a research report on Tuesday, April 10th. Seven analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $13.09.

In other vTv Therapeutics news, major shareholder Ronald O. Perelman purchased 570,776 shares of vTv Therapeutics stock in a transaction on Thursday, May 24th. The stock was bought at an average price of $4.38 per share, for a total transaction of $2,499,998.88. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 2.00% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease.

Insider Buying and Selling by Quarter for vTv Therapeutics (NASDAQ:VTVT)

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply